Abstract
Juvenile xanthogranuloma (JXG) is an uncommon non-Langerhans cell histiocytic disorder that occurs predominantly in infants. Traditional treatment of ocular JXG involves the administration of topical or local corticosteroids. We treated 2 children with JXG refractory to local corticosteroid therapy with off-label intraocular bevacizumab. To our knowledge, this is the first report of successful use of bevacizumab for ocular JXG.
Original language | English (US) |
---|---|
Pages (from-to) | 295-297 |
Number of pages | 3 |
Journal | Journal of AAPOS |
Volume | 18 |
Issue number | 3 |
DOIs | |
State | Published - Jun 2014 |
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Ophthalmology